This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Cognitive-Behavioral Therapy and Escitalopram for Generalized Anxiety Disorder(GAD)

This study has been completed.
Sponsor:
Collaborator:
Forest Laboratories
Information provided by (Responsible Party):
New York State Psychiatric Institute
ClinicalTrials.gov Identifier:
NCT00219349
First received: September 14, 2005
Last updated: April 11, 2012
Last verified: April 2012
Results First Received: February 29, 2012  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Generalized Anxiety Disorder
Interventions: Behavioral: Cognitive Behavioral-Therapy
Drug: escitalopram

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Cognitive-behavioral Therapy 14 weekly sessions of individual cognitive-behavioral therapy

Participant Flow for 2 periods

Period 1:   Cognitive Behavioral Therapy Phase
    Cognitive-behavioral Therapy
STARTED   25 
COMPLETED   15 
NOT COMPLETED   10 
Lost to Follow-up                6 
Withdrawal by Subject                2 
Protocol Violation                2 

Period 2:   Escitalopram Phase
    Cognitive-behavioral Therapy
STARTED   15 [1] 
COMPLETED   4 
NOT COMPLETED   11 
Withdrawal by Subject                4 
Physician Decision                7 
[1] 7 responders to CBT were ineligible to start and 1 declined, leaving 7 who started escitalopram



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Cognitive-behavioral Therapy 14 weekly sessions of individual cognitive-behavioral therapy

Baseline Measures
   Cognitive-behavioral Therapy 
Overall Participants Analyzed 
[Units: Participants]
 25 
Age 
[Units: Participants]
 
<=18 years   0 
Between 18 and 65 years   25 
>=65 years   0 
Age 
[Units: Years]
Mean (Standard Deviation)
 41  (11.8) 
Gender 
[Units: Participants]
 
Female   11 
Male   14 
Region of Enrollment 
[Units: Participants]
 
United States   25 


  Outcome Measures

1.  Primary:   Change in Hamilton Anxiety Rating Scale Score   [ Time Frame: week 14 to week 26 ]

2.  Primary:   Clinical Global Impressions-Improvement Index   [ Time Frame: week 26 ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

3.  Primary:   Clinical Global Impressions-Severity Index   [ Time Frame: week 14 to week 26 ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

4.  Primary:   GAD Severity Scale   [ Time Frame: week 14 to week 26 ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

5.  Primary:   Penn State Worry Questionnaire   [ Time Frame: week 14 to week 26 ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

6.  Primary:   State-Trait Anxiety Inventory   [ Time Frame: week 14 to week 26 ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

7.  Primary:   Change in Hamilton Anxiety Scale Score   [ Time Frame: week 14 to week 26 ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

8.  Secondary:   Hamilton Rating Scale for Depression   [ Time Frame: week 14 to week 26 ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

9.  Secondary:   Beck Depression Inventory-II   [ Time Frame: week 14 to week 26 ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Franklin Schneier MD
Organization: New York State Psychiatric Institute
phone: 2125435368
e-mail: fschneier@nyspi.columbia.edu


Publications of Results:

Responsible Party: New York State Psychiatric Institute
ClinicalTrials.gov Identifier: NCT00219349     History of Changes
Other Study ID Numbers: #4941
Study First Received: September 14, 2005
Results First Received: February 29, 2012
Last Updated: April 11, 2012